Short description
Neogenix Oncology develops novel therapeutic and diagnostic products for the treatment of cancer patients.
Description
Neogenix Oncology is a clinical stage bio-therapeutics company that focuses on developing novel therapeutic and diagnostic products for the treatment of pancreatic, colon, lung, prostate, and various other cancers. Its primary product, NEO-101, is a novel Phase II monoclonal antibody for colorectal and pancreatic cancer indications.
Neogenix Oncology’s product pipeline also includes NEO-201 and NEO-301, which are preclinical monoclonal antibodies for the treatment of pancreatic and colorectal cancers. The company also has a research collaboration agreement with San Raffaele-Pisana to study the expression of tumor-specific biomarkers using NEO-101, NEO-201, and NEO-301 therapeutic programs.
Headquartered in Great Neck, New York, Neogenix Oncology was founded in 2003.
Total funding
$$2020202
Sign in for full access
Location
Great Neck, New York, United States, North America
Founded on
January 1, 2003
Non-profit?
No
Acquired?
No
Employees count
11-50
Founders
Myron Arlen